Stematix Signs Contract With Laboratorios Bago
As per the agreement, Laboratorios Bago will distribute a variety of Stematix orthopedic and cellular products for use in regenerative and related medical treatments. The terms of the
The US Food and Drug Administration (FDA) is set to review Kowa Pharmaceuticals America’s new drug application (NDA) for K-911, an investigational once-daily eye drop aimed at reducing intraocular pressure (IOP) in open-angle glaucoma (OAG) or ocular hypertension (OHT) patients.